Molecular Partners AG (MOLN) - Total Liabilities

Latest as of September 2025: CHF16.62 Million CHF ≈ $21.01 Million USD

Based on the latest financial reports, Molecular Partners AG (MOLN) has total liabilities worth CHF16.62 Million CHF (≈ $21.01 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Molecular Partners AG to track the company's year-over-year net asset growth rate.

Molecular Partners AG - Total Liabilities Trend (2013–2024)

This chart illustrates how Molecular Partners AG's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Molecular Partners AG to measure how efficiently the company converts operating cash flow to free cash.

Molecular Partners AG Competitors by Total Liabilities

The table below lists competitors of Molecular Partners AG ranked by their total liabilities.

Company	Country	Total Liabilities
Fino Payments Bank Limited NSE:FINOPB	India	Rs-7.47 Billion
Cegedim S.A. PA:CGM	France	€704.39 Million
Tirathai Public Company Limited BK:TRT	Thailand	฿1.86 Billion
Shandong Xinhua Pharmaceutical Company Limited F:XIN	Germany	€3.47 Billion
Ilshin Spinnin KO:003200	Korea	₩171.07 Billion
Tavia Acquisition Corp. Unit NASDAQ:TAVIU	USA	$1.41 Million
Chant Sincere Co Ltd TW:6205	Taiwan	NT$1.14 Billion
Elme Communities NYSE:ELME	USA	$1.88 Billion

Liability Composition Analysis (2013–2024)

This chart breaks down Molecular Partners AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MOLN stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	9.28	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.17	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.15	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Molecular Partners AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Molecular Partners AG (2013–2024)

The table below shows the annual total liabilities of Molecular Partners AG from 2013 to 2024.

Year	Total Liabilities	Change
2024-12-31	CHF16.89 Million ≈ $21.35 Million	-22.95%
2023-12-31	CHF21.92 Million ≈ $27.72 Million	-19.08%
2022-12-31	CHF27.09 Million ≈ $34.25 Million	-58.56%
2021-12-31	CHF65.38 Million ≈ $82.66 Million	-18.61%
2020-12-31	CHF80.33 Million ≈ $101.55 Million	+58.13%
2019-12-31	CHF50.80 Million ≈ $64.22 Million	-19.95%
2018-12-31	CHF63.45 Million ≈ $80.22 Million	+129.12%
2017-12-31	CHF27.69 Million ≈ $35.01 Million	-42.67%
2016-12-31	CHF48.30 Million ≈ $61.07 Million	-28.55%
2015-12-31	CHF67.60 Million ≈ $85.47 Million	+48.44%
2014-12-31	CHF45.54 Million ≈ $57.57 Million	-26.31%
2013-12-31	CHF61.80 Million ≈ $78.13 Million	--

About Molecular Partners AG

SW:MOLN Switzerland Biotechnology

Market Cap

$158.87 Million

CHF125.66 Million CHF

Market Cap Rank

#17707 Global

#181 in Switzerland

Share Price

CHF3.36

Change (1 day)

+0.90%

52-Week Range

CHF2.75 - CHF3.95

All Time High

CHF38.40